ArticleOncology letters2015
Elevated Src expression associated with hepatocellular carcinoma metastasis in northern Chinese patients.
Article in Oncology letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Targeting SRC to mediate solasonine's anti-cancer activity in hepatocellular carcinoma and its potential for multi-cancer therapy.Frontiers in oncology · 2026Article
- Computational Network Pharmacology, Molecular Docking, and Molecular Dynamics to Decipher Natural Compounds ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Deep learning-based pathway-centric approach to characterize recurrent hepatocellular carcinoma after liver transplantation.Human genomics · 2024Article
- Increased c‑SRC expression is involved in acquired resistance to lenvatinib in hepatocellular carcinoma.Oncology letters · 2023Article
- Multifaceted roles of aerobic glycolysis and oxidative phosphorylation in hepatocellular carcinoma.PeerJ · 2023Review
- The Pyrazolo[3,4-Biomedicines · 2022Article
- Investigation of Anti-Liver Cancer Activity of the Herbal Drug FDY003 Using Network Pharmacology.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Investigations of nitazoxanide molecular targets and pathways for the treatment of hepatocellular carcinoma using network pharmacology and molecular docking.Frontiers in pharmacology · 2022Article
- The Persistence of Hepatitis C Virus Infection in Hepatocytes Promotes Hepatocellular Carcinoma Progression by Pro-Inflammatory Interluekin-8 Expression.Biomedicines · 2021Article
- Dysregulation of Wnt/β-catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application.Cancer science · 2021Review
- Drug Discovery in Liver Disease Using Kinome Profiling.International journal of molecular sciences · 2021Review
- c-Src kinase impairs the expression of mitochondrial OXPHOS complexes in liver cancer.Cellular signalling · 2020Article
- Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma.BMC cancer · 2020Article
- Article
- Oncogene Lin28B increases chemosensitivity of colon cancer cells in a let-7-independent manner.Oncology letters · 2018Article
- Up-regulation of CTD-2547G23.4 in hepatocellular carcinoma tissues and its prospective molecular regulatory mechanism: a novel qRT-PCR and bioinformatics analysis study.Cancer cell international · 2018Article
- A comprehensive insight into the clinicopathologic significance of miR-144-3p in hepatocellular carcinoma.OncoTargets and therapy · 2017Article
- EF24 Suppresses Invasion and Migration of Hepatocellular Carcinoma CellsBioMed research international · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Src, a non-receptor type of tyrosine, was recently reported to modulate multiple signaling pathways in human tumors. Therefore, the present study aimed to determine the expression and distribution of Src on hepatocellular carcinoma (HCC). The expressions of total Src (t-Src) and an active form of Src [phosphorylated (p-) Y416Src] were analyzed in 52 northern Chinese patients with HCC using immunohistochemistry. The positive expression rates of t-Src and p-Y416Src in HCC tissue were 65.38 and 42.30%, respectively, which is significantly higher than that in adjacent non-tumor tissue (30.76 and 13.46%; P<0.001 and P=0.010, respectively). The staining intensity of t-Src and p-Y416Src were also significantly higher in HCC tissues compared with adjacent normal tissues (P<0.001 and P=0.023, respectively). t-Src expression was positively and significantly correlated with tumor stage (P=0.002), cellular differentiation (P=0.007), metastasis (P=0.030) and the expression level of CA19-9 (P=0.016), while p-Y416Src expression was only significantly correlated with tumor stage (P=0.010). The expression of t-Src and p-Y416Src were also investigated using immunocytochemistry in two HCC cell lines with different metastatic potentials (MHCC97-L and HCCLM3) that are derived from a single HCC patient. Consistently, the expression of t-Src and p-Y416Src were stronger in the cells with higher metastatic potential compared with those exhibiting lower metastatic potential. Taken together, the current data indicate that Src expression is elevated and active in Chinese patients with HCC and that t-Src may have a key role in promoting HCC metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.